Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures (2017 - 2026)

Rocket Pharmaceuticals has disclosed Gains from Sales and Divestitures across 8 years of filings, most recently posting $803054.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $803054.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $803054.0 (changed N/A YoY), and the FY2023 annual result was $408119.0, up 947.37% from the prior year.
• Gains from Sales and Divestitures came in at $803054.0 for Q1 2026 at Rocket Pharmaceuticals, down from $825320.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $825320.0 in Q3 2025 to a low of $10168.0 in Q1 2022.
• The 5-year median for Gains from Sales and Divestitures is $355195.0 (2023), against an average of $351605.0.
• Across the five-year window, Gains from Sales and Divestitures jumped 2872.77% in 2023 and climbed 8.4% in 2025, its largest moves.
• Rocket Pharmaceuticals' Gains from Sales and Divestitures stood at $38966.0 in 2022, then surged by 947.37% to $408119.0 in 2023, then jumped by 44.13% to $588217.0 in 2024, then soared by 40.31% to $825320.0 in 2025, then decreased by 2.7% to $803054.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $803054.0 (Q1 2026), $825320.0 (Q3 2025), and $478289.0 (Q2 2025), per Business Quant data.